AR065787A1 - Tetrahidroquinolinas sustituidas - Google Patents
Tetrahidroquinolinas sustituidasInfo
- Publication number
- AR065787A1 AR065787A1 ARP080101128A ARP080101128A AR065787A1 AR 065787 A1 AR065787 A1 AR 065787A1 AR P080101128 A ARP080101128 A AR P080101128A AR P080101128 A ARP080101128 A AR P080101128A AR 065787 A1 AR065787 A1 AR 065787A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- pnr2
- pcf3
- substituted
- ocor
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos de la formula (1) donde R1 es H, A, Hal, SA, (CH2)pCN, SCN, (CF2)pCF3, SF5, OA, O(CF2)pCF3, S(CF2)pCF3, NR2, NRCOR, NRSO2R, NR(CH2)pNR2, CONR(CH2)pNR2, SO2NR(CH2)pNR2, CONR2, SO2NR2, COOR, R2 es H, Hal, R3 es H, A, A es alquilo linealo ramificado C1-10 o cicloalquilo C3-7, R4 es arilo o heteroarilo no sustituido o mono- o polisustituido con arilo o heteroarilo, que puede estar sustituido con Hal, NO2, CN, A, OR, OCOR, NR2, CF3, OCF3, OCH(CF3)2, Hal, NO2, CN, OR, A, -(CY2)n- OR, -OCOR, -(CY2)n-CO2R, -(CY2)n-CN o -(CY2)n-NR2, Y es H, A, Hal, OR; R es H, A, (CH2)pO(CH2)pR3, (CH2)pNA(CH2)pR3; W es CH2, C=O, C=S; Q1 es NR, O S, Z es -SO2-, -SO-, formulas (2), Q2 es NR, S, O o un enlace simple, R5 es H, (CY2)pNR2, (CY2)pOR,(CY2)pSR, formula (3), (CY2)pQ1COQ1R, (CY2)pCOOR y, siempre que Q2 sea un enlace simple, también Hal, Hal es F, Br o Cl, n es 1, 2, 3 o 4, m es 0, 1, o 2, p es 0, 1, 2, 3, 4 , 5, 6, 7 u 8, y s es 0, 1 o 2, así como sus derivados, solvatos,tautomeros, sales y estereoisomeros, incluyendo sus mezclas en todas las proporciones. Se pueden utilizar, entre otras cosas, para el tratamiento de tumores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007013855A DE102007013855A1 (de) | 2007-03-20 | 2007-03-20 | Substituierte Tetrahydrochinoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065787A1 true AR065787A1 (es) | 2009-07-01 |
Family
ID=39456401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101128A AR065787A1 (es) | 2007-03-20 | 2008-03-19 | Tetrahidroquinolinas sustituidas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8524732B2 (es) |
| EP (1) | EP2121700B1 (es) |
| JP (1) | JP5480636B2 (es) |
| KR (1) | KR20090120005A (es) |
| CN (1) | CN101641362A (es) |
| AR (1) | AR065787A1 (es) |
| AU (1) | AU2008228565B2 (es) |
| BR (1) | BRPI0808938A2 (es) |
| CA (1) | CA2681256C (es) |
| DE (1) | DE102007013855A1 (es) |
| EA (1) | EA200901179A1 (es) |
| ES (1) | ES2394535T3 (es) |
| IL (1) | IL200964A (es) |
| MX (1) | MX2009009916A (es) |
| WO (1) | WO2008113451A1 (es) |
| ZA (1) | ZA200907305B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011084439A1 (en) * | 2009-12-17 | 2011-07-14 | Sanofi | Tetrahydrocarboline derivatives as eg5 inhibitors |
| US9263716B2 (en) * | 2013-02-21 | 2016-02-16 | Lutron Electronics Co., Inc. | Monolithic battery holder having resilient retention strap for use in battery-powered sensor |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| EP3253747B1 (en) | 2015-02-02 | 2019-11-27 | Forma Therapeutics, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸 |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5428051A (en) | 1992-10-13 | 1995-06-27 | University Of North Carolina | Methods of combating pneumocystis carinii pneumonia and compounds useful therefor |
| EP0657422B1 (en) | 1993-12-09 | 1998-06-10 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives as PGE2 agonists and antagonists |
| US5602172A (en) | 1994-05-06 | 1997-02-11 | The University Of North Carolina At Chapel Hill | Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor |
| US5521189A (en) | 1994-05-06 | 1996-05-28 | The University Of Nc At Ch | Methods of treating pneumocystis carinii pneumonia |
| US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| US5723495A (en) | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
| ES2198139T3 (es) | 1998-08-20 | 2004-01-16 | The University Of North Carolina At Chapel Hill | Compuestos de dibenzotiofeno y procedimientos de uso de los mismos. |
| US6326395B1 (en) | 1998-09-17 | 2001-12-04 | Duke University | Antifungal activity of dicationic molecules |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| AU779923B2 (en) | 1999-07-08 | 2005-02-17 | Georgia State University | Novel prodrugs for antimicrobial amidines |
| US6325395B1 (en) | 2000-02-07 | 2001-12-04 | Jeffrey L. Frymoyer | Wheeled buoyant decoy transporting device |
| US6569853B1 (en) | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US7250423B2 (en) | 2001-09-24 | 2007-07-31 | Chao-Jun Li | Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers |
| DE502004012458D1 (de) | 2003-12-20 | 2011-06-09 | Merck Patent Gmbh | Tetrahydropyranochinolinderivate |
| DE102005027170A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| JP4655821B2 (ja) * | 2005-08-23 | 2011-03-23 | 株式会社日立製作所 | 脳機能計測用刺激呈示装置 |
-
2007
- 2007-03-20 DE DE102007013855A patent/DE102007013855A1/de not_active Withdrawn
-
2008
- 2008-02-21 EA EA200901179A patent/EA200901179A1/ru unknown
- 2008-02-21 AU AU2008228565A patent/AU2008228565B2/en not_active Ceased
- 2008-02-21 BR BRPI0808938-8A patent/BRPI0808938A2/pt not_active IP Right Cessation
- 2008-02-21 CN CN200880008909A patent/CN101641362A/zh active Pending
- 2008-02-21 EP EP08715916A patent/EP2121700B1/de not_active Not-in-force
- 2008-02-21 US US12/532,002 patent/US8524732B2/en not_active Expired - Fee Related
- 2008-02-21 CA CA2681256A patent/CA2681256C/en not_active Expired - Fee Related
- 2008-02-21 WO PCT/EP2008/001353 patent/WO2008113451A1/de not_active Ceased
- 2008-02-21 KR KR1020097021595A patent/KR20090120005A/ko not_active Withdrawn
- 2008-02-21 MX MX2009009916A patent/MX2009009916A/es not_active Application Discontinuation
- 2008-02-21 ES ES08715916T patent/ES2394535T3/es active Active
- 2008-02-21 JP JP2009553936A patent/JP5480636B2/ja not_active Expired - Fee Related
- 2008-03-19 AR ARP080101128A patent/AR065787A1/es unknown
-
2009
- 2009-09-15 IL IL200964A patent/IL200964A/en active IP Right Grant
- 2009-10-19 ZA ZA200907305A patent/ZA200907305B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010521503A (ja) | 2010-06-24 |
| DE102007013855A1 (de) | 2008-09-25 |
| MX2009009916A (es) | 2009-10-19 |
| BRPI0808938A2 (pt) | 2014-08-19 |
| IL200964A (en) | 2016-10-31 |
| KR20090120005A (ko) | 2009-11-23 |
| CN101641362A (zh) | 2010-02-03 |
| ES2394535T3 (es) | 2013-02-01 |
| CA2681256A1 (en) | 2008-09-25 |
| AU2008228565B2 (en) | 2012-09-20 |
| US20100022579A1 (en) | 2010-01-28 |
| CA2681256C (en) | 2015-06-02 |
| US8524732B2 (en) | 2013-09-03 |
| ZA200907305B (en) | 2010-06-30 |
| IL200964A0 (en) | 2010-05-17 |
| JP5480636B2 (ja) | 2014-04-23 |
| EP2121700A1 (de) | 2009-11-25 |
| WO2008113451A1 (de) | 2008-09-25 |
| AU2008228565A1 (en) | 2008-09-25 |
| EP2121700B1 (de) | 2012-10-03 |
| EA200901179A1 (ru) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065787A1 (es) | Tetrahidroquinolinas sustituidas | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR053994A1 (es) | Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos | |
| AR053569A1 (es) | Derivados de pirazol | |
| AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| PE20120798A1 (es) | Potentes inhibidores de molecula pequena de autofagia | |
| AR068748A1 (es) | Derivados de piridina activadores de glucoquinasa | |
| CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| ES2607952T3 (es) | Derivados tricíclicos de Pirazol Amina | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| SV2011003825A (es) | Nuevos derivados de acilaminobenzamida | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR073369A1 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
| AR067346A1 (es) | Derivados de bencimidazol | |
| ES2529691T3 (es) | Derivados de 3-amino-imidazo [1,2-A] piridina como inhibidores de SGLT | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| AR083635A1 (es) | Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales | |
| NO20074763L (no) | (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR065786A1 (es) | Derivados de pirimidinas condensadas con heterociclos,procedimiento de preparacion,medicamentos que las contienen y usos como inhibidores de proteinas motoras mitoticas,en el tratamiento del cancer. | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| AR054232A1 (es) | Derivados de piridina -2- carboxamida como antagonistas de mglur5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |